Abstract:Objective:To evaluate the efficacy and safety of 80 or 160 mg/day valsartan in Chinese adult patients with essential hypertension and albuminuria.Methods:A multicenter prospective open-label observational study was conducted. Adult hypertensive patients with albuminuria were treated with 80 or 160 mg/day valsartan. Blood pressure (BP) was recorded at weeks 4, 8 and 12. Albuminuria was selectively measured at week 12.Results:The intent-to-treat (ITT) population included 1180 patients. Mean sitting systolic BP (MSSBP) and diastolic BP (MSDBP) at baseline was 153.5 [14.41] (mean [SD]) and 88.2 [11.99] (mean [SD]) mmHg. MSSBP and MSDBP at week 4 (mean [SD]: 139.1 [12.02] and 82.2 [8.54] mmHg), week 8 (mean [SD]: 135.3 [10.46] and 80.2 [7.55] mmHg) and week 12 (mean [SD]: 132.1 [9.80] and 78.1 [6.88] mmHg) were significantly lower than baseline (p<0.001). The BP control rate of ITT patients at week 12 was 17.8%. Diabetic patients exhibited lower BP control rate than non-diabetic patients (14.0 vs. 22.4%, p<0.001). A total of 904 patients had albuminuria assessed at week 12. UACR and UAER at week 12 were lower compared with baseline (p<0.05). In all, 171 patients (18.9%) returned to normal albuminuria and albuminuria normalization percentage in diabetic patients exceeded that of non-diabetic patients (26.3 vs. 12.1%, p<0.001). Albuminuria declined by more than 50% in 340 patients (37.6%) and more diabetic patients exhibited such decline in albuminuria than non-diabetic patients (41.7 vs. 33.8%, p<0.05). No serious drug-related adverse effects (AEs) were observed.Limitations:Prior antihypertensive treatment before valsartan administration may interfere with the efficacy of subsequent treatment. The discrepancy between 80 and 160 mg may affect patient outcomes and occurrence of AEs.Conclusions:Valsartan can safely and effectively reduce BP and albuminuria in Chinese adult patients with essential hypertension and albuminuria. Valsartan has the more dramatic effect on albuminuria in diabetic patients than non-diabetic patients.

Overview of Clinical Use and Side Effect Profile of Valsartan in Chinese Hypertensive Patients

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Therapeutic Efficacy of Valsartan and Valsartan/hctz in Mild to Moderate Hypertensive Patients

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Efficacy and Tolerability of Once-Daily 160 Mg Valsartan in Chinese Patients with Mild to Moderate Hypertension.

Effect of Valsartan on the Level of Vwf in Patients with Hypertension and Metabolic Syndrome

Amlodipine/Valsartan 5/160 Mg Versus Valsartan 160 Mg In Chinese Hypertensives

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

Effect on Blood Pressure Control of Switching from Valsartan Monotherapy to Losartan/hydrochlorothiazide in Asian Patients with Hypertension: Results of a Multicentre Open-Label Trial

Effects of Compound Valsartan in Patients with Mild to Moderate Essential Hypertension

Influence of valsartan on Microalbuminuria of Essential Hypertensive Patients

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Efficacy and Safety of Valsartan in Reducing Blood Pressure and Albuminuria in Chinese Patients with Essential Hypertension: a Multicenter Prospective Open-Label Observational Study

Clinical effect and safety of nifedipine controlled-release tablets combined with valsartan in the treatment of primary hypertension

Clinical study on hydrochlorothiazide combined with valsartan in treatment of elderly hypertension

China STudy of Valsartan/amlodipine Fixed-Dose Combination-Based Long-Term Blood Pressure Management in HypertenSive Patients: a One-Year Registry (china STATUS III)

Valsartan/Amlodipine Compared to Nifedipine GITS in Patients with Hypertension Inadequately Controlled by Monotherapy

Effect of combining valsartan and amlodipine in the treatment of type 2 diabetes mellitus complicated by hypertension

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

The Antihypertensive Efficacy and Safety of Benazepril in Chinese Population: a Meta-Analysis of Randomized Controlled Trials